--- title: "Protagonist Therapeutics, Inc. (PTGX.US)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/PTGX.US.md" symbol: "PTGX.US" name: "Protagonist Therapeutics, Inc." industry: "Biotechnology" datetime: "2026-05-22T02:19:20.364Z" locales: - [en](https://longbridge.com/en/quote/PTGX.US.md) - [zh-CN](https://longbridge.com/zh-CN/quote/PTGX.US.md) - [zh-HK](https://longbridge.com/zh-HK/quote/PTGX.US.md) --- # Protagonist Therapeutics, Inc. (PTGX.US) ## Company Overview Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. | Item | Detail | |------|--------| | Industry | Biotechnology | | Exchange | US Market | | Website | [www.protagonist-inc.com](https://www.protagonist-inc.com) | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: D > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-05-21T04:30:16.000Z **Overall: D (0.64)** **Industry**: Biotechnology | Metric | Value | |--------|-------| | Industry Ranking | 205 / 385 | | Industry Median | C | | Industry Average | C | - **Style**: Blend - Stocks in which the company has both growth and mature businesses. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. **Multi Score**: D #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | -64.36% | | | Net Profit YoY | -304.14% | | | P/B Ratio | 9.90 | | | Dividend Ratio | 0.00% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 6487731308.24 | | | Revenue | 74063000.00 | | #### Multi Score Score: D | Indicator | Value | Rating | |-----------|-------|--------| | ROE | -17.06% | E | | Profit Margin | -154.88% | E | | Gross Margin | 100.00% | A | | Revenue YoY | -64.36% | E | | Net Profit YoY | -304.14% | E | | Total Assets YoY | -6.02% | D | | Net Assets YoY | -4.87% | D | | Cash Flow Margin | 101.68% | C | | OCF YoY | -64.36% | E | | Turnover | 0.10 | E | | Gearing Ratio | 6.02% | A | ```chart-data:radar { "title": "Longbridge Financial Score - Protagonist Therapeutics, Inc.", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "-64.36%", "rating": "" }, { "name": "Net Profit YoY", "value": "-304.14%", "rating": "" }, { "name": "P/B Ratio", "value": "9.90", "rating": "" }, { "name": "Dividend Ratio", "value": "0.00%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "6487731308.24", "rating": "" }, { "name": "Revenue", "value": "74063000.00", "rating": "" } ] }, { "name": "Multi Score", "grade": "D", "indicators": [ { "name": "ROE", "value": "-17.06%", "rating": "E" }, { "name": "Profit Margin", "value": "-154.88%", "rating": "E" }, { "name": "Gross Margin", "value": "100.00%", "rating": "A" }, { "name": "Revenue YoY", "value": "-64.36%", "rating": "E" }, { "name": "Net Profit YoY", "value": "-304.14%", "rating": "E" }, { "name": "Total Assets YoY", "value": "-6.02%", "rating": "D" }, { "name": "Net Assets YoY", "value": "-4.87%", "rating": "D" }, { "name": "Cash Flow Margin", "value": "101.68%", "rating": "C" }, { "name": "OCF YoY", "value": "-64.36%", "rating": "E" }, { "name": "Turnover", "value": "0.10", "rating": "E" }, { "name": "Gearing Ratio", "value": "6.02%", "rating": "A" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | -57.19 | 538/385 | 115.27 | 80.15 | 60.90 | | PB | 10.01 | 385/385 | 9.75 | 7.92 | 5.01 | | PS (TTM) | 88.58 | 249/385 | 89.87 | 24.44 | 16.55 | | Dividend Yield | 0.00% | - | - | - | - | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A | | 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A | | 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A | | 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A | | 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A | ## Institutional View ### Analyst Rating Distribution > As of 2026-05-21T04:00:00.000Z Total Analysts: **13** | Rating | Count | Percentage | |--------|-------|-----------| | Buy | 9 | 69% | | Overweight | 3 | 23% | | Hold | 1 | 8% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 102.01 | | Highest Target | 125.00 | | Lowest Target | 97.00 | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/PTGX.US/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/PTGX.US/norm.md) - [Related News](https://longbridge.com/en/quote/PTGX.US/news.md) - [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/PTGX.US/filings.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**